Regeneron Reports Nearly Four-Year Libtayo Data in High-Risk CSCC

C-POST data showed a 37% reduced risk of death with adjuvant Libtayo (HR 0.63; 95% CI 0.36–1.11), with sustained disease-free survival benefits despite 88% crossover from placebo after recurrence.